Company Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.
It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products.
The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.
Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs.
The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.
It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases.
In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin.
The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.
InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 1981 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Eric Adams |
Contact Details
Address: 885 West Georgia Street, Suite 1445 Vancouver, BC V6C 3E8 Canada | |
| Phone | 604 669 7207 |
| Website | inmedpharma.com |
Stock Details
| Ticker Symbol | INM |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001728328 |
| CUSIP Number | 457637601 |
| ISIN Number | CA4576376012 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric A. Adams B.S. Chem., M.I.B. | President, Chief Executive Officer and Director |
| N. Netta Jagpal | Chief Financial Officer and Corporate Secretary |
| Michael Woudenberg P.Eng. | Chief Operating Officer |
| Alexandra Diane-Janet Mancini M.Sc. | Senior Vice President of Clinical and Regulatory Affairs |
| Dr. Eric Chih-Hsien Hsu Ph.D. | Senior Vice President of Preclinical Research and Development |
| Dr. Sazzad Hossain M.Sc., Ph.D. | Co-Founder |
| Colin Clancy | Senior Director of Investor Relations |
| Jerry P. Griffin | Vice President of Sales and Marketing |
| Dr. Shane A. Johnson Ph.D. | Senior Vice President and GM of BayMedica |
| Dr. Ado Muhammad | Senior Consultant of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 5, 2025 | 424B3 | Prospectus |
| Aug 1, 2025 | EFFECT | Notice of Effectiveness |
| Aug 1, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 28, 2025 | 8-K | Current Report |
| Jul 9, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 24, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |
| May 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 16, 2025 | DEF 14A | Other definitive proxy statements |